News

Cerebrolysin® improves Blood-Brain-Barrier (BBB) Integrity

Reduction of tPA/fibrin-impaired BBB permeability
read more

New Webinar: The relevance of neurorehabilitation in acute and chronic stroke

What are the European initiatives to reduce the burden of longterm disabilities after stroke and which are the successful rehabilitation concepts?
read more
1 … 40 41 42 43 44 … 67
1 … 34
Go to Archive

Congresses

11th European Stroke Organisation Conference

Helsinki, Finland
21 - 23 May 2025
GO TO EVENT

17th World Stroke Congress

Barcelona, Spain
22 - 25 October 2025
GO TO EVENT

Notice to U.S. Visitors

Please be advised that Cerebrolysin is not registered with the U.S. Food and Drug Administration (FDA) and is not approved for sale or distribution in the United States.

Cerebrolysin is a prescription medication for use under the supervision of an authorized health care professional. For any medical inquiries, please consult with a healthcare professional.